CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Genomic Health, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Genomic Health, Inc.
301 Penobscot Drive
Phone: (650) 556-9300p:650 556-9300 Redwood City, CA  94063-4700  United States Fax: (302) 636-5454f:302 636-5454

This company was Merged or Acquired on 11/8/2019.
This company ceased filing statements with the SEC on 11/18/2019.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes--Yes

Industries
SIC Code Description
8071 Medical laboratories

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President Kevin T.Conroy 54 11/8/2019 11/8/2019
Chief Executive Officer Kimberly J.Popovits 61 11/8/2019 2/1/2002
Chief Financial Officer Jeffrey T.Elliott 42 11/8/2019 11/8/2019
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Genomic Health Canada, Limited
Genomic Health Deutschland GmbH
Genomic Health France SAS
9 additional Business Names available in full report.

General Information
Number of Employees: 829 (As of 12/31/2018)
Outstanding Shares: 37,587,598 (As of 10/28/2019)
Shareholders: 37
Stock Exchange: NASD
Federal Tax Id: 770552594
Fax Number: (302) 636-5454


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023